Seres Therapeutics (MCRB) EV to CFO (2015 - 2026)
Seres Therapeutics' (MCRB) quarterly EV to CFO came in at 2.77 in Q2 2026, up 29.15% year-over-year from 2.14 in Q2 2025, and up 18.09% quarter-over-quarter from 3.38 in Q1 2026.
Powered by 
Analysis
Seres Therapeutics (MCRB) EV to CFO (2015 - 2026) Analysis & Trends
Seres Therapeutics has disclosed EV to CFO across 12 years of filings, most recently posting 2.77 for Q2 2026.
- In Q2 2026, EV to CFO rose 29.15% year-over-year to 2.77; the TTM figure through Jun 2026 stood at 1.21 (down 39.62% YoY), while the FY2025 annual figure was 86.33, up 11456.22% from the prior year.
- EV to CFO came in at 2.77 for Q2 2026 at Seres Therapeutics, up from 3.38 in the prior quarter.
- In the past five years, EV to CFO ranged from a high of 54.85 in Q3 2025 to a low of 9.83 in Q4 2022.
- Average EV to CFO over 5 years is 0.19, with a median of 2.74 recorded in 2024.
- Year-over-year, EV to CFO tumbled 794.5% in 2022 and soared 2119.55% in 2025.
- Over 5 years, EV to CFO stood at 9.83 in 2022, then soared by 86.91% to 1.29 in 2023, then tumbled by 125.91% to 2.91 in 2024, then slumped by 125.62% to 6.56 in 2025, then surged by 57.81% to 2.77 in 2026.
- Per Business Quant data, the three most recent EV to CFO figures were 2.77 in Q2 2026, 3.38 in Q1 2026, and 6.56 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Seres Therapeutics | 49.89 Mn | 49.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.77 |
| Mar 31, 2026 | -3.38 |
| Dec 31, 2025 | -6.56 |
| Sep 30, 2025 | 54.85 |
| Jun 30, 2025 | -3.90 |
| Mar 31, 2025 | 2.36 |
| Dec 31, 2024 | -2.91 |
| Sep 30, 2024 | -2.72 |
| Jun 30, 2024 | -0.97 |
| Mar 31, 2024 | -0.17 |
| Dec 31, 2023 | -1.29 |
| Sep 30, 2023 | -2.30 |
| Jun 30, 2023 | 5.82 |
| Mar 31, 2023 | -7.98 |
| Dec 31, 2022 | -9.83 |
| Sep 30, 2022 | -9.03 |
| Jun 30, 2022 | -1.04 |
| Mar 31, 2022 | -4.72 |
| Dec 31, 2021 | -9.15 |
| Sep 30, 2021 | 1.30 |